scholarly journals Defining Transcription Regulatory Elements in the Human Frataxin Gene: Implications for Gene Therapy

2020 ◽  
Vol 31 (15-16) ◽  
pp. 839-851 ◽  
Author(s):  
Jixue Li ◽  
Yanjie Li ◽  
Jun Wang ◽  
Trevor J. Gonzalez ◽  
Aravind Asokan ◽  
...  
Blood ◽  
2010 ◽  
Vol 116 (25) ◽  
pp. 5507-5517 ◽  
Author(s):  
Claudia Cattoglio ◽  
Danilo Pellin ◽  
Ermanno Rizzi ◽  
Giulietta Maruggi ◽  
Giorgio Corti ◽  
...  

Abstract Integration of retroviral vectors in the human genome follows nonrandom patterns that favor insertional deregulation of gene expression and increase the risk of their use in clinical gene therapy. The molecular basis of retroviral target site selection is still poorly understood. We used deep sequencing technology to build genomewide, high-definition maps of > 60 000 integration sites of Moloney murine leukemia virus (MLV)– and HIV-based retroviral vectors in the genome of human CD34+ multipotent hematopoietic progenitor cells (HPCs) and used gene expression profiling, chromatin immunoprecipitation, and bioinformatics to associate integration to genetic and epigenetic features of the HPC genome. Clusters of recurrent MLV integrations identify regulatory elements (alternative promoters, enhancers, evolutionarily conserved noncoding regions) within or around protein-coding genes and microRNAs with crucial functions in HPC growth and differentiation, bearing epigenetic marks of active or poised transcription (H3K4me1, H3K4me2, H3K4me3, H3K9Ac, Pol II) and specialized chromatin configurations (H2A.Z). Overall, we mapped 3500 high-frequency integration clusters, which represent a new resource for the identification of transcriptionally active regulatory elements. High-definition MLV integration maps provide a rational basis for predicting genotoxic risks in gene therapy and a new tool for genomewide identification of promoters and regulatory elements controlling hematopoietic stem and progenitor cell functions.


2021 ◽  
pp. 0271678X2110396 ◽  
Author(s):  
Hanna Graßhoff ◽  
Helge Müller-Fielitz ◽  
Godwin K Dogbevia ◽  
Jakob Körbelin ◽  
Jacqueline Bannach ◽  
...  

Gene vectors targeting CNS endothelial cells allow to manipulate the blood-brain barrier and to correct genetic defects in the CNS. Because vectors based on the adeno-associated virus (AAV) have a limited capacity, it is essential that the DNA sequence controlling gene expression is short. In addition, it must be specific for endothelial cells to avoid off-target effects. To develop improved regulatory sequences with selectivity for brain endothelial cells, we tested the transcriptional activity of truncated promoters of eleven (brain) endothelial-specific genes in combination with short regulatory elements, i.e., the woodchuck post-transcriptional regulatory element (W), the CMV enhancer element (C), and a fragment of the first intron of the Tie2 gene (S), by transfecting brain endothelial cells of three species. Four combinations of regulatory elements and short promoters ( Cdh5, Ocln, Slc2a1, and Slco1c1) progressed through this in-vitro pipeline displaying suitable activity. When tested in mice, the regulatory sequences C- Ocln-W and C- Slc2a1-S-W enabled a stronger and more specific gene expression in brain endothelial cells than the frequently used CAG promoter. In summary, the new regulatory elements efficiently control gene expression in brain endothelial cells and may help to specifically target the blood-brain barrier with gene therapy vectors.


Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 497-497 ◽  
Author(s):  
Phillip W. Hargrove ◽  
Steven Kepes ◽  
Hideki Hanawa ◽  
Cheng Cheng ◽  
Geoff Neale ◽  
...  

Abstract The development of lymphoid leukemia in two children with X-SCID who underwent gene therapy was partially due to activation of the LMO-2 proto-oncogene by the retroviral LTR of the vector which inserted nearby (Hacein-Bey-Abina et al., Science 2003), highlighting the importance of vector design on the potential to activate genes near vector integration sites. As gene therapy vectors for other blood disorders are evaluated, it seems prudent to assess the safety issues regarding insertion for each particular vector in appropriate pre-clinical models. We have focused on developing γ-globin lentiviral vectors for gene therapy of the hemoglobin disorders and have documented correction of a murine model of β-thalassemia in the absence of observable adverse events (Persons et al., Blood 2003; Hanawa et al., Blood 2004). To more thoroughly evaluate the potential for vector-induced genotoxicity, we have examined whether self-inactivating (SIN) γ-globin lentiviral vectors containing erythroid-specific, β-globin locus enhancer elements can alter the expression of genes nearby the vector insertion site, as the retroviral LTR did in the X-SCID trial. To ascertain whether an integrated globin vector could influence endogenous transcriptional activity in erythroid precursors, 15 clonal spleen colony erythroblast populations (≥ 95% erythroid) containing lentiviral globin vector insertions and 15 untransduced control clones were derived from bone marrow cells of β-thalassemic mice. The transcriptional profile of each clone was determined using the Affymetrix Mouse 430A microarray (representing ~15,000 genes). Expression of 4500–6000 genes was observed in all samples. Ligation-mediated PCR was used to obtain the vector-genomic DNA junction sequences, allowing identification of vector insertion locations in 13 of the clones using the NCBI database. Of these, 6 globin vector clones had 16 genes, including N-ras, which were located within 100kb of the vector insertion site and were represented on the array. Only one gene, D3Jfr1, encoding a “cold shock” DNA binding protein and which was disrupted by an intronic vector insertion, had a change in signal value relative to the mean signal value of the controls. Real time RT-PCR confirmed a 4-fold reduction in expression of this gene. Both microarray and real time RT-PCR demonstrated that expression of N-ras was unchanged. For comparison, 15 clones with insertions of a lentiviral vector containing the MSCV retroviral LTR, were also derived, along with 10 additional mock control clones. We are currently analyzing the expression of some 116 genes that lie within 300kb of the vector insertions, relative to the mean expression level in the 25 mock transduced clones. Additionally, we have expanded analysis of the globin vector clones to evaluate changes in expression of 107 genes located within 300kb of the vector insertions. These data should prove useful to assess whether integrated SIN globin lentiviral vectors containing erythroid-specific regulatory elements have a propensity to alter transcriptional activity in the progeny of genetically modified hematopoietic stem cells, relative to vectors containing viral LTR elements.


2006 ◽  
Vol 80 (1) ◽  
pp. 27-37 ◽  
Author(s):  
Weidong Xiong ◽  
Shyam Goverdhana ◽  
Sandra A. Sciascia ◽  
Marianela Candolfi ◽  
Jeffrey M. Zirger ◽  
...  

ABSTRACT In view of recent serious adverse events and advances in gene therapy technologies, the use of regulatable expression systems is becoming recognized as indispensable adjuncts to successful clinical gene therapy. In the present work we optimized high-capacity adenoviral (HC-Ad) vectors encoding the novel tetracycline-dependent (TetOn)-regulatory elements for efficient and regulatable gene expression in the rat brain in vivo. We constructed two HC-Ad vectors encoding β-galactosidase (β-gal) driven by a TetOn system containing the rtTASsM2 transactivator and the tTSKid repressor under the control of the murine cytomegalovirus (mCMV) (HC-Ad-mTetON-β-Gal) or the human CMV (hCMV) promoter (HC-Ad-hTetON-β-Gal). Expression was tightly regulatable by doxycycline (Dox), reaching maximum expression in vivo at 6 days and returning to basal levels at 10 days following the addition or removal of Dox, respectively. Both vectors achieved higher transgene expression levels compared to the expression from vectors encoding the constitutive mCMV or hCMV promoter. HC-Ad-mTetON-β-Gal yielded the highest transgene expression levels and expressed in both neurons and astrocytes. Antivector immune responses continue to limit the clinical use of vectors. We thus tested the inducibility and longevity of HC-Ad-mediated transgene expression in the brain of rats immunized against adenovirus by prior intradermal injections of RAds. Regulated transgene expression from HC-Ad-mTetON-β-Gal remained active even in the presence of a significant systemic immune response. Therefore, these vectors display two coveted characteristics of clinically useful vectors, namely their regulation and effectiveness even in the presence of prior immunization against adenovirus.


Author(s):  
BJ Aronow ◽  
CA Ley ◽  
KC Ess ◽  
DP Witte

The formation of peripheral T cells from thymocyte progenitors is an intricate developmental process that requires the organized and coordinate expression of multiple genes. Adenosine deaminase (ADA) is an example of a gene that is subject to strong developmental regulation in T-cell precursors and is essential for the subsequent formation of T-cells in humans. We have sought to understand the mechanisms of ADA gene regulation from a basic point of view as well as to employ this to potential vectors for gene therapy.Using transgenic mice have shown that the first intron of the ADA gene contains a powerful locus control region that directs high level gene expression within cortical thymocytes. Based on extensive mutational analysis of the regulatory region and analyses of gene expression that include quantitative gene expression, in situ hybridization, and biochemical characterizations of chromatin structure, we have demonstrated that the intronic locus control region (LCR) consists of a hierarchically structured 2300 base pairs of DNA sequence (Figure 1). The LCR is composed of a series of regulatory elements that include a centrally positioned 300 base pair classical enhancer domain within which there is a critical 30 base pair enhancer core. Within this core, there is a single binding site for the transcription factor c-Myb that is required for activity of the enhancer core, the enhancer, and the intact LCR. Beyond the 300 bp enhancer core on either side the LCR contains novel and puzzling 1 kb non-enhancer sequences that we have termed facilitators. These sequences enable gene copy proportional expression by facilitating the ability of the enhancer to function in chromatin. The effects of the facilitators are evidenced by their ability to allow for insertion-site-independent and gene-copy-proportional expression and they prevent variegated expression among similarly differentiated cell types (Figure 2). Thus, total gene expression does not indicate proper cell type specific expression. The facilitators also allow for the formation of a strong tissue and cell type specific DNAse I hypersensitive site at the enhancer. This suggests that the formation of a discrete organized chromatin structure as a function of developmental differentiation requires extensive DNA sequences, only some of which are of the enhancer type. The capabilities of the facilitators to activate a chromatin domain may also suggest their potential usefulness in vectors for gene therapy of both ADA deficiency and possibly other human genetic diseases. However, the distance and non-enhancer nature of the facilitators suggest that they may act differently than conventional regulatory elements. In support of this, the facilitators obey a strict position and orientation rules with respect to the enhancer.


2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Mei Lin ◽  
Junxing Huang ◽  
Yujuan Shi ◽  
Yanhong Xiao ◽  
Ting Guo

Radiation-gene therapy, a dual anticancer strategy of radiation therapy and gene therapy through connecting radiation-inducible regulatory sequence to therapeutic gene, leading to the gene being induced to express by radiation while radiotherapy is performed and finally resulting in a double synergistic antitumor effect of radiation and gene, has become one of hotspots in the field of cancer treatment in recent years. But under routine dose of radiation, especially in the hypoxia environment of solid tumor, it is difficult for this therapy to achieve desired effect because of low activity of radiation-inducible regulatory elements, low level and transient expression of target gene induced by radiation, inferior target specificity and poor biosecurity, and so on. Based on the problems existing in radiation-gene therapy, many efforts have been devoted to the curative effect improvement of radiation-gene therapy by various means to increase radiation sensitivity or enhance target gene expression and the expression’s controllability. Among these synergistic techniques, gene circuit, hypoxic sensitization, and optimization of radiation-induced sequence exhibit a good application potential. This review provides the main influential factors to radiation-gene therapy on cancer and the synergistic techniques to improve the anticancer effect of radiation-gene therapy.


JCI Insight ◽  
2020 ◽  
Vol 5 (16) ◽  
Author(s):  
Hongjie Wang ◽  
Aphrodite Georgakopoulou ◽  
Chang Li ◽  
Zhinan Liu ◽  
Sucheol Gil ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document